Press releases
These press releases are intended for journalists and analysts/investors.
-
2013 Corporate Responsibility Report Published
GSK Australia and New Zealand today published the second annual corporate responsibility report, outlining key achievements in health
-
Positive poppy trial results encourage on-going investigation
Positive results from GSK’s 2013-14 poppy growing trials across Victoria will provide a sound foundation for more targeted trials
-
GSK discloses 2013 payments to Australian healthcare professionals
As part of our ongoing commitment to increase transparency, we are disclosing today, the aggregate amount of fees paid
-
GSK encourages research excellence as award nominations open
GSK has opened nominations for what is regarded as one of the most prestigious research awards available to the Australian science
-
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and COPD
GSK Australia and Theravance, Inc. (NASDAQ: THRX) have proudly announced today that the Therapeutic Goods Administration (TGA)
-
GSK innovation starts to relieve the urge to smoke in 50 seconds
GSK Australia launched today a new innovative product Nicabate Oral Strips that starts to* relieve the urge to smoke in just 50 seconds
-
Illuminate your smile with the new Macleans® High Definition™ White range
We all know how important it is to present our best possible self, unleashing the unmistakable feeling of illumination
-
Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer
GlaxoSmithKline plc (LSE:GSK) today announced its decision to stop the MAGRITi trial
-
GSK brings New Zealand to the forefront in new Panadol® brand campaign
A Kiwi father and son will star in a brand new Panadol campaign to be aired on television screens globally
-
GSK Recalls Nicotine Lozenges from Warehouses and Distributors
GSK is in the process of voluntarily recalling from warehouses and distributors a number of batches of nicotine lozenges sold globally
-
New PBS listing for patients with advanced soft tissue sarcoma
Treatment options for advanced Soft Tissue Sarcoma (STS) have been broadened with a new Pharmaceutical Benefits Scheme (PBS)
-
TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)
GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies
-
Supply of Varilrix® and Priorix-Tetra® resumes
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing
-
Poppy Crop Security Update
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports
-
Supply of Varilrix® and Priorix-Tetra®
GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines
-
GSK announces changes to its global sales and marketing practices
GSK announced today changes to the way products are marketed and sold to healthcare professionals to further align the company’s activities
-
Poppy Trials Making Positive Progress
Victoria is one step closer to commercial poppy growing, with scientific trials undertaken by GlaxoSmithKline (GSK) Australia
-
GSK recalls from trade two batches of Children’s Panadol® 1-5 years Suspension
GSK is working with the Therapeutic Goods Administration (TGA) to recall two batches of Children’s Panadol® 1-5 years Suspension
-
New medicine listed on the PBS for the treatment of metastatic melanoma in Australia
The listing of Tafinlar® (dabrafenib mesilate) on the Pharmaceutical Benefits Scheme (PBS) will lead to improved access to the medicine
-
URGENT SAFETY ALERT - Syringe Dosing Device for Children’s Panadol
GlaxoSmithKline (GSK) is initiating a recall of Children’s Panadol Baby Drops Syringe dosing device due to possible inaccurate placement
